Chemotherapy plus immunotherapy for ear canal cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests combining chemotherapy with the immunotherapy drug tislelizumab for advanced squamous cell carcinoma of the ear canal. It may help shrink tumors that haven't spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have squamous cell carcinoma of the outer ear canal that is locally advanced (stage T3 or T4) and has not spread to distant organs.
- You have not had any previous treatment for this cancer.
- You are generally healthy enough to undergo chemotherapy and immunotherapy (ECOG score 0 or 1).
- Your blood counts, liver, and kidney function are within acceptable ranges before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (tirilizumab) and two chemotherapy drugs (albumin-bound paclitaxel and cisplatin) for people with advanced but removable oral cancer. The goal is to see if this treatment shrinks the tumor before surgery and improves outcomes.
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
This trial tests a combination of drugs (tislelizumab, cetuximab, and chemotherapy) before and after surgery for people whose mouth or throat cancer has returned after previous treatment. The goal is to see if this approach can help shrink or control the cancer and improve outcomes.
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
This Phase 2 study tests whether tislelizumab (an immunotherapy) combined with chemotherapy works better for locally advanced head and neck squamous cell cancer. It aims to improve cancer control when the tumor is large and has not spread to distant organs.
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
Hear when a new Squamous Cell Carcinoma of External Auditory Canal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.